Lucid Diagnostics designates Series C convertible preferred stock
Lucid Diagnostics filed a Certificate of Designation establishing Series C Convertible Preferred Stock Series for up to 15,000 shares, aimed at future financings.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed